Literature DB >> 26740214

Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.

Lars Jønson1, Lise B Ahlborn1, Ane Y Steffensen1, Malene Djursby2, Bent Ejlertsen3, Susanne Timshel4, Finn C Nielsen1, Anne-Marie Gerdes2, Thomas V O Hansen5.   

Abstract

Germ-line mutations in the RAD51C gene have recently been identified in families with breast and ovarian cancer and have been associated with an increased risk of ovarian cancer. In this study, we describe the frequency of pathogenic RAD51C mutations identified in Danish breast and/or ovarian cancer families. We screened the RAD51C gene in 1228 Danish hereditary breast and/or ovarian cancer families by next-generation sequencing analysis. The frequency of the identified variants was examined in the exome sequencing project database and in data from 2000 Danish exomes and the presumed significance of missense and intronic variants was predicted by in silico analysis. We identified six families with a pathogenic mutation in RAD51C, including three frameshift mutations, one nonsense mutation, and 2 missense mutations. Overall, pathogenic RAD51C mutations were identified in 0.5 % of Danish families with increased risk of hereditary breast and/or ovarian cancer. Moreover, we identified 24 additional RAD51C variants of which 14 have not been previously reported in the literature. In this study, we determine the prevalence of RAD51C mutations in Danish breast and/or ovarian cancer families. We identified six pathogenic RAD51C mutations as well as 23 variants of uncertain clinical significance and one benign variant. Together, the study extends our knowledge of the RAD51C mutation spectrum and supports that RAD51C should be included in gene panel testing of individuals with high risk of breast and ovarian cancer.

Entities:  

Keywords:  Breast cancer; In silico analysis; Mutation; Novel; Ovarian cancer; RAD51C

Mesh:

Substances:

Year:  2016        PMID: 26740214     DOI: 10.1007/s10549-015-3674-y

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  13 in total

1.  Genetic screening of the FLCN gene identify six novel variants and a Danish founder mutation.

Authors:  Maria Rossing; Anders Albrechtsen; Anne-Bine Skytte; Uffe B Jensen; Lilian B Ousager; Anne-Marie Gerdes; Finn C Nielsen; Thomas vO Hansen
Journal:  J Hum Genet       Date:  2016-10-13       Impact factor: 3.172

2.  Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.

Authors:  Na Li; Simone McInerny; Magnus Zethoven; Dane Cheasley; Belle W X Lim; Simone M Rowley; Lisa Devereux; Norah Grewal; Somayeh Ahmadloo; David Byrne; Jue Er Amanda Lee; Jason Li; Stephen B Fox; Thomas John; Yoland Antill; Kylie L Gorringe; Paul A James; Ian G Campbell
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

3.  Exceptional response to FOLFIRINOX in a patient with pancreatic cancer and a germline RAD51C mutation.

Authors:  Sofia Palacio; Terri Pollack; Rachel Silva-Smith; Daniel A Sussman; Peter J Hosein
Journal:  J Gastrointest Oncol       Date:  2018-08

Review 4.  Hereditary breast and ovarian cancer: new genes in confined pathways.

Authors:  Finn Cilius Nielsen; Thomas van Overeem Hansen; Claus Storgaard Sørensen
Journal:  Nat Rev Cancer       Date:  2016-08-12       Impact factor: 60.716

5.  A recurrent pathogenic BRCA2 exon 5-11 duplication in the Christian Arab population in Israel.

Authors:  Hagit Baris-Feldman; Karin Weiss; Gili Reznick Levi; Gal Larom; Vered Ofen Glassner; Nina Ekhilevitch; Nitzan Sharon Swartzman; Tamar Paperna
Journal:  Fam Cancer       Date:  2021-05-17       Impact factor: 2.446

6.  Clinical characteristics and registry-validated extended pedigrees of germline TP53 mutation carriers in Denmark.

Authors:  Ulrik Stoltze; Anne-Bine Skytte; Henriette Roed; Henrik Hasle; Bent Ejlertsen; Thomas van Overeem Hansen; Kjeld Schmiegelow; Anne-Marie Gerdes; Karin Wadt
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

7.  Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.

Authors:  Rita D Brandão; Klaas Mensaert; Irene López-Perolio; Demis Tserpelis; Markos Xenakis; Vanessa Lattimore; Logan C Walker; Anders Kvist; Ana Vega; Sara Gutiérrez-Enríquez; Orland Díez; Miguel de la Hoya; Amanda B Spurdle; Tim De Meyer; Marinus J Blok
Journal:  Int J Cancer       Date:  2019-02-07       Impact factor: 7.396

Review 8.  Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases.

Authors:  Anja Frederiksen; Maria Rossing; Pernille Hermann; Charlotte Ejersted; Rajesh V Thakker; Morten Frost
Journal:  J Clin Endocrinol Metab       Date:  2019-09-01       Impact factor: 5.958

9.  Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer.

Authors:  Barbara Wappenschmidt; Jan Hauke; Ulrike Faust; Dieter Niederacher; Lisa Wiesmüller; Gunnar Schmidt; Evi Groß; Andrea Gehrig; Christian Sutter; Juliane Ramser; Andreas Rump; Norbert Arnold; Alfons Meindl
Journal:  Geburtshilfe Frauenheilkd       Date:  2020-04-21       Impact factor: 2.915

10.  A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect.

Authors:  Lesa M Dawson; Kerri N Smith; Salem Werdyani; Robyn Ndikumana; Cindy Penney; Louisa L Wiede; Kendra L Smith; Justin A Pater; Andrée MacMillan; Jane Green; Sheila Drover; Terry-Lynn Young; Darren D O'Rielly
Journal:  Mol Genet Genomic Med       Date:  2019-11-28       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.